Bicara Therapeutics (BCAX) Other Non-Current Liabilities (2023)

Bicara Therapeutics (BCAX) reported Other Non-Current Liabilities of $17000.0 for Q4 2023.

Bicara Therapeutics (BCAX) Other Non-Current Liabilities (2023) Analysis & Trends

Bicara Therapeutics has reported Other Non-Current Liabilities for 1 years, with the latest figure at $17000.0 in Q4 2023.

For the quarter ending Q4 2023, Other Non-Current Liabilities changed N/A year-over-year to $17000.0; the trailing twelve-month figure through Dec 2023 stood at $17000.0 (changed N/A YoY), and the FY2023 full-year result was $17000.0, changed N/A from the prior year.
Other Non-Current Liabilities for Q4 2023 stood at $17000.0.
The five-year high for Other Non-Current Liabilities was $17000.0 in Q4 2023, with the low at $17000.0 in Q4 2023.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Bicara Therapeutics	1.41 Bn	1.41 Bn	-

Historic Data

Download Data

Date	Value
Dec 31, 2023	17,000.00